	Application No.	Applicant(s)
Notice of Allowability		
	10/706,291 Examiner	SHITAGAKI ET AL.  Art Unit
	Laminer	Artonic
	Marie R. Yamnitzky	1794
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. X This communication is responsive to RCE filed Oct. 15, 2007 with Amendment and Certified Translation of Foreign Priority.		
2. The allowed claim(s) is/are 15-27 and 29-32 (renumbered as 1-17, respectively).		
3. ☑ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) ☑ All b) ☐ Some* c) ☐ None of the:		
1. Certified copies of the priority documents have been received.		
2. Certified copies of the priority documents have been received in Application No		
3. Copies of the certified copies of the priority documents have been received in this national stage application from the		
International Bureau (PCT Rule 17.2(a)).		
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.  THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
5. CORRECTED DRAWINGS ( as "replacement sheets") must be submitted.		
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review ( PTO-948) attached		
1)  hereto or 2)  to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachment(s)		
1. Notice of References Cited (PTO-892)	5. Notice of Informal F	• •
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	6.  ☐ Interview Summary Paper No./Mail Da	
<ol> <li>Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date</li> </ol>	Paper No./Mail Da 7. ⊠ Examiner's Amend	ment/Comment
4. Examiner's Comment Regarding Requirement for Deposit of Biological Material	8. 🛛 Examiner's Statem	ent of Reasons for Allowance
<u>-</u>	9.	

Art Unit: 1794

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submissions (amendment and certified translation of foreign priority document) filed on October 15, 2007 have been entered.

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

The application has been amended as follows:

In the specification:

Page 4, line 2: "PLOBLEM" has been changed to -- PROBLEM--.

Page 15, in the chemical name under the first formula following line 10: "fran" has been changed to --furan--.

## In the abstract:

In the first line following "ABSTRACT": "has" has been changed to --have--.

In the fourth line following "ABSTRACT": "is" has been changed to --are--.

Application/Control Number: 10/706,291

Art Unit: 1794

The amendment filed October 15, 2007 amends claim 15 and adds claims 30-32.

The rejections of claim 15 under 35 U.S.C. 102(a) and claim 21 under 35 U.S.C. 103(a)

are withdrawn in view of the amendment to claim 15 and the contents of applicant's foreign

priority application.

Claims 15-27 and 29-32 are allowed.

The following is an examiner's statement of reasons for allowance:

The prior art does not disclose or suggest an electroluminescent device in which a light-

emitting layer comprises a quinoxaline derivative represented by the formula defined in any of

independent claims 15-19 and 30.

Any comments considered necessary by applicant must be submitted no later than the

payment of the issue fee and, to avoid processing delays, should preferably accompany the issue

fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for

Allowance."

Any inquiry concerning this communication should be directed to Marie R. Yamnitzky at telephone number (571) 272-1531. The examiner works a flexible schedule but can generally be reached at this number from 7:00 a.m. to 3:30 p.m. Monday-Friday.

The current fax number for all official faxes is (571) 273-8300. (Unofficial faxes to be sent directly to examiner Yamnitzky can be sent to (571) 273-1531.)

**MRY** 

November 01, 2007

MARIE YAMNITZKY

Maire R. Charactefy

Page 3

1794